Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aptose Biosciences, Inc.
< Previous
1
2
Next >
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
October 16, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Present at the Cantor Global Healthcare Conference
September 18, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
September 06, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Reports Results for the Second Quarter 2023
August 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
June 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Presents Highlights from Clinical Update
June 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences Provides Update on Reverse Stock Split
June 05, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Reports Results for the First Quarter 2023
May 08, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
April 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Reports Results for the Fourth Quarter and Full Year 2022
March 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
March 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
January 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
December 28, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Tickers
APTO
TSX:APS
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.